Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Midodrine Plus Albumin Versus Midodrine Alone to Prevent Cirrhosis Related Complications in Children With Cirrhosis and Ascites
NCT06091345Completed
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Dec 2023
- Primary completion
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of albumin (human) in Liver cirrhosis (LC) and ascites (2 arms), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Composite incidence of complications of cirrhosis at 6 months. Started Dec 2023; status: completed.
02
Drugs
albumin (human)
03
Conditions
Liver cirrhosis (LC)ascites
Beyond the preview
Go deeper on NCT06091345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06091345.